New Alzheimer's drug candidate passes first safety check in small trial
NCT ID NCT06285240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and how the body handles a new drug called MK-1167 in 28 people with Alzheimer's who were already taking donepezil. The study was completed and focused on side effects and drug levels in the blood. It does not yet show whether MK-1167 helps with memory or thinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1167
What this could lead to
If successful, this could point toward a new add-on treatment to ease Alzheimer's symptoms when combined with donepezil.
What could go wrong
This is a very early Phase 1 safety study with only 28 people. It does not test whether MK-1167 actually improves symptoms or slows the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel iResearch, LLC ( Site 0003)
Decatur, Georgia, 30030, United States
-
CenExel iResearch, LLC ( Site 0004)
Savannah, Georgia, 31405, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, 33009, United States